# Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

> **NCT04376814** · NA · COMPLETED · sponsor: **Baqiyatallah Medical Sciences University** · enrollment: 40 (actual)

## Conditions studied

- COVID-19
- Favipiravir
- Kaletra
- Hydroxychloroquine
- Lopinavir/Ritonavir

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Hydroxychloroquine
- **DRUG:** Lopinavir / Ritonavir

## Key facts

- **NCT ID:** NCT04376814
- **Lead sponsor:** Baqiyatallah Medical Sciences University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-29
- **Primary completion:** 2020-04-05
- **Final completion:** 2020-05-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04376814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04376814, "Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04376814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*